Follow Us:
Monday, July 04, 2022

Eli Lilly,Boehringer ink pact to sell diabetes drugs in India

The collaboration includes Eli Lilly's insulin analogue,Humalog (Lispro).

Written by Agencies | New Delhi |
October 3, 2011 7:37:35 pm

Drug firms Eli Lilly India and Boehringer Ingelheim India today said they are entering into a India specific pact to co-promote a portfolio of diabetes compounds,currently either in late-stage development or already in the market.

The collaboration includes Eli Lilly’s insulin analogue,Humalog (Lispro),which is already in the Indian market,and Boehringer Ingelheim’s oral anti-diabetic agent,Linagliptin,not yet approved for marketing in India,the firms said in a joint statement.

The alliance will leverage the collective scientific expertise and business capabilities of the research-driven pharmaceutical companies to address patient needs arising from growing global diabetes epidemic,it said.

“The new alliance will significantly increase marketing efforts behind the Humalog range,including pre-mixed insulins. As a result,a greater number of health care providers across India will now have access to the Humalog range of products,” it added.

Best of Express Premium
UPSC Essentials: Key terms of the past weekPremium
ExplainSpeaking: Despite the fall, are Indian stock markets still overval...Premium
‘Peter Brook tried to destroy, recreate us. I wasn’t willing to be destro...Premium
In Gujarat, Covid crisis brings estranged couples together for second chancePremium

According to IMS Indian Pharmaceutical Audit,June 2011,from the time of its launch in 2005,Lilly’s Humalog range has today has become a significant player in the nearly USD 30 million premix and rapid insulin analog market.

“This strategic alliance with Boehringer Ingelheim will significantly expand our commercial presence in India and will allow us to better serve many more patients reiterating our commitment to play a leading role in fighting diabetes in India,” Eli Lilly and Company Emerging Markets Business Area president Jacques Tapiero said.

On the development,Boehringer Ingelheim Emerging Markets Head Philipp von Lattorff said the agreement will provide both the firms combined benefits in India –Lilly’s expertise in the diabetes market as well as Boehringer Ingelheim’s rich and innovative late-stage pipeline.

Express Explained Go beyond the news. Understand the headlines with our Explained stories

📣 Join our Telegram channel (The Indian Express) for the latest news and updates

For all the latest News Archive News, download Indian Express App.

  • Newsguard
  • The Indian Express website has been rated GREEN for its credibility and trustworthiness by Newsguard, a global service that rates news sources for their journalistic standards.
  • Newsguard